HC Wainwright set a $1.00 price target on Diffusion Pharmaceuticals (NASDAQ:DFFN) in a report released on Thursday. The brokerage currently has a buy rating on the stock.

Separately, ValuEngine upgraded Diffusion Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, November 1st.

Shares of NASDAQ DFFN opened at $0.32 on Thursday. The firm has a market capitalization of $15.96 million, a P/E ratio of -0.28 and a beta of -1.43. Diffusion Pharmaceuticals has a one year low of $0.30 and a one year high of $2.08.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last issued its earnings results on Wednesday, November 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.07). Research analysts predict that Diffusion Pharmaceuticals will post -0.43 EPS for the current fiscal year.

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Read More: How to use beta for portfolio diversification

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.